Wolfe Research Downgrades Insmed to Peer Perform
Wolfe Research analyst Andy Chen downgrades Insmed (NASDAQ:INSM) from Outperform to Peer Perform.
Share
Why It Matters
A stock expert thinks Insmed is now just okay, not great anymore. When experts change their mind like this, it hints they see fewer exciting reasons to own it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.